☆ 4.7 Meeting Abstract

Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study

ANNALS OF ONCOLOGY (2022)

Journal

ANNALS OF ONCOLOGY

Volume 33, Issue -, Pages S206-S207

Publisher

ELSEVIER

DOI: 10.1016/j.annonc.2022.03.194

Keywords

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study

Journal

ANNALS OF ONCOLOGY

Publisher

ELSEVIER

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study

Journal

ANNALS OF ONCOLOGY

Publisher

ELSEVIER

Keywords

Categories

Ask authors/readers for more resources

Protocol

Reagent

Authors

I am an author on this paper

Reviews

Primary Rating

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Recommended

Export Citation

Share Paper